Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus...

Area of Science:

• Hepatology
• Immunology
• Public Health

Background:

• The impact of baseline characteristics and treatment outcomes on autoimmune disease development in chronic hepatitis C (CHC) patients is not well understood.
• Pegylated interferon plus ribavirin (PR) was a common CHC treatment, but its effect on autoimmune diseases requires investigation.

Purpose of the Study:

• To investigate the association between baseline characteristics, virological profiles, and therapeutic outcomes of PR therapy with the incidence of autoimmune diseases in CHC patients.
• To identify predictors for the development of autoimmune diseases, specifically systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), in this cohort.

Main Methods:

• A nationwide cohort of 12,770 CHC patients treated with PR therapy was established using the Taiwanese Chronic Hepatitis C Cohort and linked to the National Health Insurance Research Database.
• Follow-up data over 67,930 person-years were analyzed to determine the incidence of 10 autoimmune diseases.
• Statistical analyses, including hazard ratios, were used to identify independent predictors for SLE/RA incidence.

Main Results:

• The annual incidence of SLE or RA was 0.03%.
• A body mass index (BMI) ≥24 kg/m² was an independent predictor of a lower incidence of SLE or RA (HR 0.40, p=0.034).
• Achieving a sustained virological response (SVR) to PR therapy was not associated with a reduced incidence of SLE or RA.

Conclusions:

• Higher BMI may be a protective factor against developing SLE or RA in CHC patients treated with PR therapy.
• SVR to PR therapy does not appear to influence the subsequent development of SLE or RA in CHC patients.